Chelsea Pratt
cpratt@investingnewsnetwork.com
Articles
What Is In-Licensing?
Licensing deals might be pharma’s preferred mode of business development these days—perhaps even more so than outright acquisitions.
February 19th, 2018
Genetics Facts for Investors
Punnett squares and phenotypes, chromatids and codominance: genetics, and all of its associated terms, isn’t the easiest field to understand....
March 9th, 2017
The Potential of Transdermal Drug Delivery
Drugs with low oral bioavailability risk failure in clinical trial: minimal absorption, after all, can translate to reduced efficacy. As...
March 2nd, 2017
The CRISPR-Cas9 Patent Dispute
The US Patent Office has ruled “no interference in fact” on CRISPR-Cas9 Patent dispute.
February 15th, 2017
How Medicine Uses Artificial Intelligence
Artificial intelligence is revolutionizing technology, but also medicine. Here’s how.
February 15th, 2017
What Are Mesenchymal Stem Cells?
What exactly are mesenchymal stem cells … and more importantly, why should investors care?
February 9th, 2017
What Are Biologics?
Herceptin, Enbrel, Botox: at first glance, these therapies may appear to have little in common.
February 8th, 2017
10 Drugs Going Off-Patent in 2017
When generic competitors enter the market, sales from a blockbuster drug can decrease significantly.
January 26th, 2017
Beyond Medical Marijuana: Investment Opportunities in Cannabis-Based Biotechs
From serums and masks to oral sprays and enriched waters, we’re counting down the novel ways in which some cannabis-based...
January 25th, 2017
What Is Regenerative Medicine?
The body already has amazing regenerative abilities—can we not harness that power and, in turn, amplify it?
January 18th, 2017
